Further combination treatment with nec-1 provided significant additional protection by about 20%, which might indicate a necroptotic cell death induced by TRAIL/bortezomib in HNSCC cells (Figure 2a). Here, TNFSF10 is linked to head and neck squamous cell carcinoma.